GlassScriptPhysician profile
William A Schukay
NPI 1952318305
$10,941.54
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,376 · 2020: $2,124 · 2021: $3,290 · 2022: $3,152.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,268.05 | 2019-2022 | |
| Abbvie INC. | $1,109.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,036.30 | 2019-2022 | |
| Glaxosmithkline, LLC. | $831.13 | 2019-2022 | |
| Lilly USA, LLC | $698.33 | 2019-2022 | |
| Amarin Pharma, INC. | $621.74 | 2019-2022 | |
| Amgen INC. | $600.81 | 2019-2022 | |
| Pfizer INC. | $589.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $413.50 | 2019-2022 | |
| Astellas Pharma US INC | $388.39 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $382.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.00 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $355.02 | 2021 | |
| Sanofi-Aventis U.S. LLC | $291.58 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $244.67 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.68 | 2019-2022 | |
| Allergan, INC. | $193.70 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $193.47 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $190.36 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $182.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $164.49 | 2019-2022 | |
| Esperion Therapeutics, INC. | $117.44 | 2020-2022 | |
| Horizon Therapeutics Plc | $73.51 | 2019-2022 | |
| Genzyme Corporation | $60.00 | 2020 | |
| Bausch Health US, LLC | $53.84 | 2019-2022 | |
| Radius Health, INC. | $43.74 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $43.72 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.28 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $33.13 | 2021-2022 | |
| Abbott Laboratories | $28.07 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $26.27 | 2021 | |
| Biogen, INC. | $17.72 | 2022 | |
| Genentech USA, INC. | $16.80 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.20 | 2022 | |
| Endo Pharmaceuticals INC. | $13.16 | 2021 | |
| Neos Therapeutics, LP | $13.07 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Schukay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.